On September 14, 2020 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, reported that Dr. Stephen Dilly, President and CEO, will present an overview of the company at two investor conferences in September: the H.C. Wainwright 22nd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Press release, Sierra Oncology, SEP 14, 2020, View Source [SID1234565093]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright Annual Global Investment Conference
Date:
Wednesday, Sept 16
Time:
11:00 am ET
Webcast link:
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date:
Monday, September 21
Time:
11:40 am ET
Webcast Link:
Replays of these presentations will be available on the Investors section of Sierra’s corporate website in the Events & Webcast tab.